ADXN - Addex Therapeutics Trailing Twelve Months Revenue Growth

Can Addex Therapeutics (ADXN) ensure a stable cash flow in the absence of operating profit? The answer is provided by the YoY sales growth over the last four quarters, where -46.20 determines the current status of the parameter. Geopolitical tensions and logistical collapse are hindering CNS drug trials. Meanwhile, strict FDA oversight and patent protection create insurmountable barriers for new entrants.
Addex (ADXN) - metric breakdowns and financial figures

The development of allosteric modulators in partnership with global pharma behemoths creates long-term catalysts, although the current research stage has not yet transformed into active cash flow for Addex Therapeutics (ADXN). The dynamics of the annual sales growth rate (trailing 12 months) measure daily changes in TTM revenue, allowing investors to distinguish business model stability from developmental stagnation by analyzing the actual speed of cash inflows.